What is Persist AI?
Persist AI is a pioneering technology firm specializing in the intersection of artificial intelligence and pharmaceutical manufacturing. The company focuses on revolutionizing Chemistry, Manufacturing, and Controls (CMC) through the deployment of AI-driven robotics. By integrating predictive algorithms with automated laboratory systems, Persist AI enables pharmaceutical developers to optimize drug formulations with unprecedented speed and precision. This approach significantly reduces the time-to-market for novel therapeutics, addressing critical inefficiencies in the drug development pipeline across various modalities.
How much funding has Persist AI raised?
Persist AI has raised a total of $16M across 2 funding rounds:
Other Financing Round
$4M
Series A
$12M
Other Financing Round (2023): $4M with participation from 2048 Ventures, Innospark Ventures, Fellows Fund, Pioneer Fund, and Y Combinator
Series A (2025): $12M led by MBX Capital, Innospark Ventures, Spero Ventures, Good AI Capital, Purdue DIAL Ventures, SignalFire, Cartography Capital, Asymmetry Ventures, Global Brain, Y Combinator, 2048 Ventures, and Eli Lilly
Key Investors in Persist AI
MBX Capital
A boutique venture capital firm that partners with and creates healthcare and biotechnology companies that are disrupting conventions in service to public health.
SignalFire
A venture capital firm designed as a technology company, focused on igniting growth for early-stage teams through data, AI, and expert support.
Eli Lilly
A global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines across multiple therapeutic areas.
What's next for Persist AI?
With the successful closure of its Series A round, Persist AI is poised to enter a period of aggressive commercial expansion and technical refinement. The strategic focus will likely center on scaling its robotic infrastructure to accommodate a growing roster of enterprise-level pharmaceutical partners. Furthermore, the involvement of industry-specific investors suggests a roadmap aimed at deepening integration within the clinical trial and drug discovery value chain. As the company matures, it will likely prioritize the enhancement of its predictive models to further solidify its competitive advantage in the high-stakes biotech sector.
See full Persist AI company page
